| abstract |
The present disclosure relates to a novel DNA aptamer and the use thereof and, more particularly, to a DNA aptamer which is selected as to specifically bind to cancer cells from a DNA library obtained by means of a Cell-SELEX method. A DNA aptamer, of the present disclosure, which is optimized and selected as to have a strong binding force to cancer has enhanced target cell and tissue targeting efficiency and high stability in the blood, and thus can effectively be used in cancer diagnosis and the like. |